ライフサイエンスコーパス: phase 1 clinical trial

1 which has been selected for evaluation in a Phase 1 clinical trial.

2 a multicentre, open-label, dose-escalation, phase 1 clinical trial.

3 ion dosimetry of LMI1195 were evaluated in a phase 1 clinical trial.

4 tive Porcupine inhibitor being examined in a phase 1 clinical trial.

5 enhance immune responses, was evaluated in a phase 1 clinical trial.

6 Phase 1 clinical trial.

7 ease (GVHD) in mice and has shown promise in phase 1 clinical trials.

8 ed in Al(OH)3 has been tested in 3 published phase 1 clinical trials.

9 development from early hit discovery through phase 1 clinical trials.

10 i) approximately 5 pM), currently undergoing phase 1 clinical trials.

11 que antiangiogenic bispecific antibody is in phase-1 clinical trials.

12 (8S,9R)-47 has completed phase 1 clinical trial and is currently being studied in

13 Compound R,R-19a was advanced into a phase 1 clinical trial and produced a robust decrease in

14 We conducted a phase 1 clinical trial and treated 16 patients with rela

15 oxicity and eventual failure of GSK932121 in phase-1 clinical trial and highlight the need for direct

16 boxylase (AdoMetDC), is presently undergoing Phase 1 clinical trials as an experimental anticancer ag

17 One derivative, 1f, has reached phase 1 clinical trials as the prodrug 2f, Phortress (NS

18 id an open-label, uncontrolled, prospective, phase 1 clinical trial at one centre in Munich, Germany.

19 domised, partly blinded, placebo-controlled, phase 1, clinical trial at Emory University that enrolle

20 400, an indenoisoquinoline Top1 inhibitor in phase 1 clinical trial, by itself and in combination wit

21 This Phase 1 clinical trial compared the safety and immunogen

22 gn, Setting, and Participants: Single-center phase 1 clinical trial conducted in the United States of

23 Data from a phase 1 clinical trial demonstrate that oral administrat

24 ons behind the failure of PGMK30FRhL3 during phase 1 clinical trial, despite meeting the empirically

25 DENSPM)-a polyamine analogue also undergoing Phase 1 clinical trials-despite accumulating approximate

26 This phase 1 clinical trial employed a DNA prime and subunit

27 ted with a single oral dose of DADMe-ImmH in phase 1 clinical trials exhibit regain of PNP activity w

28 ified as potential candidate vaccines, and a phase 1 clinical trial has been completed that demonstra

29 els of cancer, with promising results, and a phase 1 clinical trial in cancer patients has been initi

30 to elicit serum bactericidal antibodies in a phase 1 clinical trial in humans.

31 linical use and is currently being used in a phase 1 clinical trial in patients with severe ischemic

32 elopment in 2010 and is currently undergoing phase 1 clinical trials in advanced leukemias and multip

33 (PGE2); this strategy has now progressed to phase 1 clinical trials in double cord blood transplanta

34 into development and is currently undergoing phase 1 clinical trials in healthy volunteers.

35 properties, AZD3839 has been progressed into Phase 1 clinical trials in man.

36 71 has been taken into phase 1 clinical trials in patients with multiple myelom

37 Compound 2 is currently in multiple phase 1 clinical trials in patients with small cell lung

38 Pinometostat is currently in Phase 1 clinical trials in relapsed refractory acute leu

39 has emerged from these studies and is now in phase 1 clinical trials in the U.S.

40 conjugate vaccine Pfs25-EPA/Alhydrogel is in Phase 1 clinical trials in the USA and Africa.

41 Phase 1 clinical trials indicate high levels of safety a

42 One such phase 1 clinical trial is currently under way at the MD

43 A phase 1 clinical trial is in progress to investigate the

44 ve inhibitor, currently being evaluated in a phase 1 clinical trial (NCT02637531), can reshape the tu

45 to the entry of (R)-(+) 1 (NSC 698215) into phase 1 clinical trials (NIH UO1-CA62487).

46 he results of a first-in-man dose escalation phase 1 clinical trial of 3BNC117, a potent human CD4 bi

47 Based on these data, we have embarked on a phase 1 clinical trial of addback of allo-LCL-depleted d

48 nced, ALK-positive NSCLC who enrolled in the phase 1 clinical trial of crizotinib, focusing on the co

49 On the basis of these preclinical results, a phase 1 clinical trial of decitabine followed by selinex

50 A phase 1 clinical trial of forodesine in T-cell malignanc

51 arch organization were enrolled in the first phase 1 clinical trial of TGN1412, a novel superagonist

52 le promoters; and (5) the initial reports on phase 1 clinical trials of foetal spinal cord grafts int

53 Indeed, phase 1 clinical trials of hedgehog pathway inhibitors a

54 As phase 1 clinical trials of MLN518 in AML have shown litt

55 F901318 is currently in late Phase 1 clinical trials, offering hope that the antifung

56 underwent GT in their worse-seeing eye in a phase 1 clinical trial received a second subretinal inje

57 revious studies in FA murine models and in a phase 1 clinical trial suggest that myelopreparation is

58 rationale that has led to initiation of two phase 1 clinical trials targeting GITR as a new immunoth

59 d 63) is an antibacterial agent that entered phase 1 clinical trials targeting infections caused by G

60 In a pivotal phase 1 clinical trial, the ALK tyrosine kinase inhibito

61 In a recent phase 1 clinical trial, the ALK tyrosine-kinase inhibito

62 We performed a phase 1 clinical trial to test the safety and immunologi

63 ith the high degree of selectivity, enabling Phase 1 clinical trials using a crystalline formulation

64 A phase 1 clinical trial was conducted among 35 healthy ad

65 A phase 1 clinical trial was conducted transfusing radiola

66 cancer treatment strategy in the setting of phase 1 clinical trials was analyzed.

67 In a phase 1 clinical trial, we assessed the safety and pharm

68 peutic angiogenesis." The objectives of this phase 1 clinical trial were (1) to document the safety a

69 ncouraging preclinical data pave the way for phase 1 clinical trials with CVD 915.

70 and oligodendrocytes completed a successful phase 1 clinical trial without toxic effects with the go